No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease

The 20210 G/A prothrombin gene mutation is associated with an increased ris k of venous thrombosis but whether there is an association of the mutation with premature coronary artery disease and acute myocardial infarction rema ins unclear. To further assess the role of the G/A genotype as a risk factor for arteria l vascular disease, we performed a case-control study of 644 patients aged less than 50 years with angiographically proven coronary artery disease, 40 2 of whom had myocardial infarction, and 679 unrelated healthy control subj ects aged less than 50 years, randomly selected from the electoral roll. The prevalence of the G/A genotype was 2.5% in patients with coronary arter y disease, and 3.2% in control subjects (odds ratio 0.8; 95%, confidence in terval 0.35 to 1.83). The mutation was not more frequent among patients wit h a history of myocardial infarction (2.2%, odds ratio 0.7; 95% confidence interval 0.27 to 2.05), and there was no evidence of an interaction between the prothrombin mutation and conventional cardiovascular disease risk fact ors. Then was no association between genotype and extent of angiographic co ronary artery disease (p = 0.73), We conclude that the 20210 G/A prothrombin gene mutation is not a major ris k factor for premature coronary artery disease in our predominantly Caucasi an Australian population.